FMC's Q3 Collapse Deepens: Covenant Talks, Impairment Risk and Dividend Doubts
FMC sits 15% above its 52-week low of $4.845 on elevated volume (3.5× avg).
Summary
FMC's Q3 revenue guidance was slashed to $65M-$125M from $840M-$900M, with adjusted EBITDA now guided to a loss of $510M-$565M and $625M-$675M of charges tied to price cuts and a U.S. sales restructure. The recap adds two items beyond the original Oct 15 disclosure: management expects covenant compliance at Sept. 30 but will negotiate covenant or agreement changes with lenders this year, and an impairment review of intangible assets could produce a material non-cash loss of an unestimable amount. Shares fell more than 30% Thursday after the update, and analysts have cut targets hard — Jefferies downgraded to Hold and slashed its target to $5 from $14, J.P. Morgan to $6 from $12, Mizuho to $10 from $12. The core worry is cash: tight near-term free cash flow against high debt has analysts questioning whether the dividend survives, though management has not announced a cut. Isoflex Active's possible EU registration in 2027 is the main growth offset, but that is far out and execution risk is high.
At the time of this announcement, FMC was trading at $5.58 on NYSE in the Manufacturing sector, with a market capitalization of approximately $880.4M. The 52-week trading range was $4.85 to $30.95. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.